multiplex elisa kit  (Boster Bio)

Journal: Scientific Reports

Article Title: Cold inducible RNA binding protein promotes fibroblast activation and its inhibition represents a potential therapeutic target in pulmonary fibrosis

doi: 10.1038/s41598-026-39649-3

Figure Lengend Snippet: Transcriptomic profiling and cytokine production in CIRBP-stimulated primary mouse lung fibroblasts. ( A ) Volcano plot of differentially expressed genes in fibroblasts treated with rmCIRBP vs. control. ( B ) Heatmap of representative upregulated and downregulated genes (fold change > 2.5). ( C , D ) Quantitative PCR analysis of Acta2 and Fn1 mRNA expression in fibroblasts treated with or without rmCIRBP. TGF-β–stimulated fibroblasts were included as a positive control. ( E , F ) Western blot analysis of α-SMA and fibronectin protein expression in fibroblasts treated with or without rmCIRBP. TGF-β–stimulated fibroblasts were included as a positive control. ( G – L ) ELISA quantification of cytokines in the culture supernatants: TGF-β, PDGF, IFN-γ, IL-1β, TNF-α, and IL-6. Data are presented as mean ± SEM. *P < 0.05 using one-way ANOVA and Tukey’s multiple comparison test. rmCIRBP recombinant mouse CIRBP.

Article Snippet: After 24 h of treatment, cytokine concentrations in the culture supernatants were quantified using the arigoPLEX® Mouse Proinflammatory Cytokine Multiplex ELISA Kit and the arigoPLEX® Mouse Fibrotic Marker Multiplex ELISA Kit (arigo Biolaboratories Corp., Taiwan) according to the manufacturer’s instructions.

Techniques: Control, Real-time Polymerase Chain Reaction, Expressing, Positive Control, Western Blot, Enzyme-linked Immunosorbent Assay, Comparison, Recombinant

Journal: Scientific Reports

Article Title: Cold inducible RNA binding protein promotes fibroblast activation and its inhibition represents a potential therapeutic target in pulmonary fibrosis

doi: 10.1038/s41598-026-39649-3

Figure Lengend Snippet: CIRBP promotes collagen production and proliferation via TLR2/4-dependent IL-6 signaling. ( A ) IL-6 concentrations in the culture supernatants of primary lung fibroblasts treated with rmCIRBP, with or without C23, TLR4-I, or TLR2-I, measured by ELISA. ( B ) Soluble collagen levels in the supernatants following treatment with rmCIRBP ± anti-IL-6 antibody. ( C ) Proliferative activity of fibroblasts assessed by the WST assay after treatment with rmCIRBP and/or anti-IL-6 antibody. ( D ) Soluble collagen production in fibroblasts treated with rmCIRBP and either TLR4-I or TLR2-I. ( E ) Fibroblast proliferation measured using the WST assay following cotreatment with rmCIRBP and TLR4-I or TLR2-I. ( F ) Schematic representation of the proposed mechanism: CIRBP, which is highly expressed in fibrotic lungs, stimulates IL-6 production via TLR2/4, promoting collagen secretion and fibroblast proliferation in an autocrine manner and contributing to the progression of tissue fibrosis. Data are presented as mean ± SEM. *P < 0.05 using one-way ANOVA and Tukey’s multiple comparison test.

Article Snippet: After 24 h of treatment, cytokine concentrations in the culture supernatants were quantified using the arigoPLEX® Mouse Proinflammatory Cytokine Multiplex ELISA Kit and the arigoPLEX® Mouse Fibrotic Marker Multiplex ELISA Kit (arigo Biolaboratories Corp., Taiwan) according to the manufacturer’s instructions.

Techniques: Enzyme-linked Immunosorbent Assay, Activity Assay, WST Assay, Comparison

Journal: Journal of Neuroinflammation

Article Title: The Parkinson’s disease-associated LRRK2-G2019S variant restricts serine metabolism, leading to microglial inflammation and dopaminergic neuron degeneration

doi: 10.1186/s12974-025-03577-2

Figure Lengend Snippet: Immunological phenotyping of LRRK2-G2019S microglia showed heightened activation and inflammatory profiles. A Representative analysis of mean fluorescence intensity (top) and the quantification (bottom) of activation markers (CD68, HLA-DR, CD80, and CD86) of LRRK2-WT and LRRK2-G2019S microglia. Data are shown as mean ± SD ( n = 3–4), pooled from four independent trials. B Representative analysis of mean fluorescence intensity (left) and the quantification (right) of pathogen recognition receptors TLR2 and TLR4 in LRRK2-WT and LRRK2-G2019S microglia. Data are shown as mean ± SD ( n = 3–4), pooled from four independent trials. C Flow cytometry analysis of microglia phagocytosis in LRRK2-WT and LRRK2-G2019S microglia using fluorescently labelled Zymosan beads. Representative images are shown on the left, quantification on the right. Data are shown as mean ± SD ( n = 3–4), pooled from four independent trials. D Flow cytometry analysis of microglia phagocytosis in LRRK2-WT and LRRK2-G2019S microglia using pH-sensitive fluorescent Zymosan beads. Representative images are shown on the left, quantification on the right. Data are shown as mean ± SD ( n = 3–4), pooled from four independent trials. E Enzyme-linked immunosorbent assay of human inflammatory cytokines in LRRK2-WT and LRRK2-G2019S microglia using the Human Inflammatory Cytokine Multiplex ELISA Kit from Arigo Biolaboratories. Data are shown as mean ± SD ( n = 4), representative of two independent trials. F Flow cytometry analysis of intracellular TNF-α in LRRK2-WT and LRRK2-G2019S microglia upon 24 h stimulation with LPS. Representative images are shown on the left, quantification on the right. Data are shown as mean ± SD ( n = 3–4), pooled from four independent trials. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

Article Snippet: E Enzyme-linked immunosorbent assay of human inflammatory cytokines in LRRK2-WT and LRRK2-G2019S microglia using the Human Inflammatory Cytokine Multiplex ELISA Kit from Arigo Biolaboratories.

Techniques: Activation Assay, Fluorescence, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Multiplex Assay